ASCO 2023 | Immune checkpoint inhibitors in mCRPC

Pedro Barata, MD, University Hospitals Seidman Cancer Center, Cleveland, OH, discusses the use of immune checkpoint inhibitors in the management of patients with metastatic castration-resistant prostate cancer (mCRPC), a historically “cold” tumor, highlighting the importance of biomarkers in stratifying patients likely to respond to immunotherapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.